Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,567 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 38,198 · Balance 162,567 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 202,759 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 202,759 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 156,589 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 46,170 · Balance 156,589 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 194,786 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2019 Filed Jul 18, 2019 00:16 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $16.58 | $49,740.00 |
DisclosureSEC source: 0001437749-19-014176 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.51 to $16.75 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2019 Filed Jul 18, 2019 00:16 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-014176 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 00:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-012310 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 00:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $17.47 | $52,410.00 |
DisclosureSEC source: 0001437749-19-012310 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.47 to $17.49 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 00:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-012310 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2019 Filed May 18, 2019 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-010419 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| May 15, 2019 Filed May 18, 2019 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $16.96 | $50,880.00 |
DisclosureSEC source: 0001437749-19-010419 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.87 to $17.39 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2019 Filed May 18, 2019 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-010419 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 00:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-007470 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 00:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $17.56 | $52,680.00 |
DisclosureSEC source: 0001437749-19-007470 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 00:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-007470 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-005089 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $16.67 | $50,010.00 |
DisclosureSEC source: 0001437749-19-005089 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.61 to $16.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-005089 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 02:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 6,491 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-003529 · rdgdoc.xml · derivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,491 Underlying: Common Stock · 6,491 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · derivative.exercise_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · derivative.expiration_date: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 02:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 6,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-003529 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,074 F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 02:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-002786 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 02:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $16.07 | $48,210.00 |
DisclosureSEC source: 0001437749-19-002786 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,583 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 02:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-002786 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-19-001006 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $12.12 | $36,360.00 |
DisclosureSEC source: 0001437749-19-001006 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,583 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.09 to $12.15, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-19-001006 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-18-017442 · rdgdoc.xml · derivative · entry 3 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $17.23 | $51,690.00 |
DisclosureSEC source: 0001437749-18-017442 · rdgdoc.xml · nonDerivative · entry 2 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,583 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 3,000 | $2.06 | $6,180.00 |
DisclosureSEC source: 0001437749-18-017442 · rdgdoc.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 22:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantEmployee Stock Option · Derivative | 123,209 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001144204-18-013913 · tv488201_4.xml · derivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,209 Underlying: Common Stock · 123,209 shares Expires 2021-12-20 F1 · derivative.exercise_date: As disclosed in the registrants annual report on Form 10-K for the year ended December 31, 2016, on December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock. The option vests in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 61,605 shares vested on March 8, 2018 and 61,604 shares will vest on March 8, 2019. No Form 4 filing was required upon the initial grant of the option because the option was subject to vesting based on conditions that were not tied to the passage of time and continued employment and not tied directly to the market price of the registrant's common stock. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 02:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 9,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-000673 · tv482652_4.xml · nonDerivative · entry 1 Berard Todd · CIK 0001633186 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,583 F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.